查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446930

中枢神经系统 (CNS) 治疗市场：按疾病类型：2024-2033 年全球机会分析与产业预测

Central Nervous System (CNS) Therapeutics Market By Disease Type (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 246 Pages | 商品交期: 2-3个工作天内

价格

中枢神经系统（CNS）治疗市场2023年估值为1141.4558亿美元，预计到2033年将达到1990.983亿美元，2024年至2033年复合年增长率为5.7%。中枢神经系统（CNS）是一个由神经和细胞组成的复杂网络，在协调和调节身体活动中发挥重要作用。中枢神经系统由脑和脊髓组成，是整个神经系统的主要控制中心。中枢神经系统药物旨在缓解症状、改善认知功能和减缓疾病进展。中枢神经系统治疗主要涉及使用药物来解决中枢神经系统内的疾病或失衡。它针对各种神经和神经退化性疾病阿兹海默症和帕金森氏症等神经退化性疾病到情绪障碍、焦虑症和精神病等精神疾病。

中枢神经系统（CNS）治疗市场-IMG1

由于中枢神经系统（CNS）疾病盛行率的迅速增加以及支持研究和创新的研究津贴等政府主导，中枢神经系统（CNS）治疗市场预计将显着增长。中枢神经系统（CNS）疾病的日益普及已成为中枢神经系统（CNS）治疗市场的主要驱动因素。这是由于生活方式紧张、忽视心理健康以及人口老化加剧所造成的。特别是在高龄化社会，阿兹海默症、帕金森氏症等神经退化性疾病迅速增加。例如，根据美国疾病管制与预防中心的数据，大约有 670 万 65 岁以上的美国患有阿兹海默症。

此外，现代快节奏的生活方式以高压力水平和久坐习惯为特征，与焦虑和忧郁症等精神疾病的风险增加有关。例如，根据国家医学图书馆的数据，预计到 2021 年，超过五分之一的美国成年人将患有精神疾病。製药公司越来越注重发现和开发针对各种中枢神经系统疾病的新药和治疗方法。神经科学的突破以及对这些疾病潜在机制的更深入了解为更有效和更有针对性的治疗方法铺平了道路。随着患者和医疗保健提供者寻求先进的干预措施来解决中枢神经系统疾病的根本原因而不仅仅是缓解症状，对中枢神经系统药物的需求预计将飙升。因此，中枢神经系统（CNS）疾病盛行率的增加预计将显着促进中枢神经系统（CNS）治疗市场的成长。

此外，政府的有利津贴，倡议将推动市场成长。世界各国政府已经认识到需要解决神经退化性疾病、精神疾病和神经系统疾病等疾病，这些疾病给全球医疗保健系统带来了沉重负担。促进研究的一项值得注意的倡议是提供研究津贴，专门用于提高我们对中枢神经系统的了解并开发新的治疗性介入。研究津贴作为科学研究的催化剂，促进研究人员、学术界和製药公司之间的合作。例如，美国帕金森氏症协会向研究科学家提供高达 75,000 美元的研究津贴。美国氏症协会研究津贴旨在支持旨在获得有关病理学新知识的研究。

津贴提案可以解决从基础科学到復健计划的任何研究问题。美国帕金森氏症协会旨在鼓励新研究人员进入帕金森氏症研究领域，并支持该领域值得研究的重要新想法。政府机构透过提供津贴在促进创新治疗方法和疗法的开发方面发挥着至关重要的作用。因此，研究津贴等有利的政府倡议预计将推动市场成长。

然而，中枢神经系统（CNS）治疗的高成本已成为限制市场成长的主要问题。神经系统疾病的复杂性通常需要复杂且专门的治疗性介入，从而导致高昂的研发成本。此外，卫生当局施加的严格监管要求导致中枢神经系统疾病药物上市需要漫长且资源密集的时间。这些高昂的成本转嫁给了最终用户，包括患者和医疗保健系统，限制了中枢神经系统治疗的取得和负担能力。因此，中枢神经系统（CNS）治疗的高成本可能会抑制市场成长。

中枢神经系统（CNS）治疗市场按疾病类型和地区细分。依疾病类型分为神经血管疾病、中枢神经系统创伤、精神健康、神经退化性疾病、感染疾病、癌症等。心理健康领域进一步分为心理健康焦虑症、癫痫、情绪障碍、精神障碍等。

神经退化性疾病进一步分为阿兹海默症、帕金森氏症、多发性硬化症、亨丁顿舞蹈症、肌萎缩性侧索硬化症等。依地区划分，市场分为北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙、其他欧洲国家）、亚太地区（中国、日本、澳洲、印度、韩国、其他地区） ） 、亚太地区（巴西、日本、阿拉伯、澳洲、印度、韩国和亚太地区其他地区）。

相关人员的主要利益

  • 该报告提供了 2023 年至 2033 年中枢神经系统 (CNS) 治疗市场分析的细分市场、当前趋势、估计/趋势和动态的定量分析，并提供了领先的中枢神经系统 (CNS)动态市场的定量分析分析. 确定药品市场机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商和买家网路的潜力。
  • 中枢神经系统（CNS）治疗市场区隔的详细分析有助于确定市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于对标，并可以清楚了解市场参与者的当前地位。
  • 它包括对区域和全球中枢神经系统 (CNS) 治疗市场趋势、主要企业、细分市场、应用领域、市场成长策略等的分析。

可使用此报告进行客製化（需要额外费用和时间表）

  • 根据客户兴趣加入公司简介
  • 公司简介的扩充列表
  • 历史市场资料

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 神经系统疾病盛行率上升
      • 提高对中枢神经系统疾病的认识和诊断
      • 主要企业研发快速增加
    • 抑制因素
      • 中枢神经系统（CNS）药物高成本
    • 机会
      • 药物传输技术的进步

第四章中枢神经系统（CNS）治疗市场：依疾病类型

  • 概述
  • 神经血管疾病
  • 中枢神经系统创伤
  • 精神健康
    • 按精神健康疾病类型分類的中枢神经系统 (CNS) 治疗药物市场
  • 神经退化性疾病
    • 神经神经退化性疾病的中枢神经系统 (CNS) 治疗市场：依疾病类型
  • 感染疾病
  • 中枢神经系统癌症
  • 其他的

第五章中枢神经系统（CNS）治疗市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第六章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2023年主要企业定位

第七章 公司简介

  • Johnson and Johnson
  • Eli Lilly and Company.
  • Merck & Co Inc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche AG
  • Takeda Pharmaceutical Company Ltd.
  • Viatris Inc.
  • UCB Pharma
  • Biogen
Product Code: A305147

The Central Nervous System (CNS) Therapeutics Market was valued for $114,145.58 million in 2023 and is estimated to reach $199,098.30 million by 2033, exhibiting a CAGR of 5.7% from 2024 to 2033. The central nervous system (CNS) is a complex network of nerves and cells that play a crucial role in coordinating and regulating the body's activities. It comprises the brain and spinal cord, serving as the primary control center for the entire nervous system. Central nervous system therapeutics aim to alleviate symptoms, improve cognitive function, and slow down disease progression. Central nervous system therapeutics primarily involve the use of drugs to address disorders and imbalances within the central nervous system. The medications target various neurological and psychiatric conditions, ranging from neurodegenerative diseases like Alzheimer's and Parkinson's to mental health disorders such as mood disorders, anxiety, and psychotic disorders.

Central Nervous System (CNS) Therapeutics Market - IMG1

The central nervous system (CNS) therapeutics market is expected to register significant growth, owing to surge in prevalence of CNS disorders, and favorable government initiative such as research grants to support research and innovation. The rise in prevalence of CNS disorders has emerged as a major driver for the central nervous system (CNS) therapeutics market. This can be attributed to the stressful lifestyle, negligence towards mental health, and rise in geriatric population. The aging population, in particular, has witnessed a surge in neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. For instance, according to Center for Disease Control and Prevention, it was estimated that around 6.7 million Americans aged 65 years or older had Alzheimer's disease.

Additionally, the modern, fast-paced lifestyle, marked by high stress levels and sedentary habits, has been associated with a heightened risk of mental health disorders like anxiety and depression. For instance, according to National Library of Medicine, in 2021, it was estimated that that more than one in five U.S. adults live with a mental illness. Pharmaceutical companies are increasingly focusing on the discovery and development of novel drugs and therapies targeting various CNS conditions. Breakthroughs in neuroscience and a deeper understanding of the underlying mechanisms of these disorders have paved the way for more effective and targeted treatment options. The demand for CNS therapeutics is expected to surge as patients and healthcare providers seek advanced interventions that not only alleviate symptoms but also address the root causes of the CNS disorders. Thus, the rise in prevalence of CNS disorders is expected to contribute significantly to the growth of the central nervous system (CNS) therapeutics market.

In addition, favorable government initiatives such as research grants to support research and innovation in treating central nervous system disorders are expected to drive the growth of the market. Governments around the world are recognizing the critical need to address conditions such as neurodegenerative diseases, psychiatric disorders, and neurological disorders, which collectively pose a substantial burden on global healthcare systems. One notable initiative driving the research is the provision of research grants specifically dedicated to advancing our understanding of the central nervous system and developing novel therapeutic interventions. The research grants serve as a catalyst for scientific exploration, fostering collaboration between researchers, academia, and pharmaceutical companies. For instance, American Parkinson Disease Association, awards research grant of maximum of $75,000 to research scientists. American Parkinson Disease Association Research Grants are intended to support research aimed at developing new insights into the pathophysiology, etiology and treatment of Parkinson's disease.

Grant proposals can address research questions anywhere along the pipeline from basic science to rehabilitation-focused projects. American Parkinson Disease Association seeks to promote the entry of new investigators into the field of Parkinson research, as well as to support important new ideas in the field worthy of investigation. By providing grants governments agencies are playing a pivotal role in accelerating the development of innovative treatments and therapies. Thus, favorable government initiatives such as research grants are expected to drive the growth of the market.

However, the high cost of the central nervous system (CNS) therapeutic drug has emerged as major concerns restraining the growth of the market. The complex nature of neurological disorders often necessitates sophisticated and specialized therapeutic interventions, leading to elevated research and development expenses. Additionally, the stringent regulatory requirements imposed by health authorities contribute to the lengthy and resource-intensive process of bringing CNS drugs to market. These substantial costs are then transferred to end-users, comprising patients and healthcare systems, thereby limiting accessibility and affordability of the CNS drugs. Thus, the high cost of the central nervous system (CNS) therapeutic drug might restrain the growth of the market.

The central nervous system (CNS) therapeutics market is segmented based on disease type and region. By disease type, it is divided into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, cancer, and others. The mental health segment is further segmented into mental health anxiety disorders, epilepsy, mood disorders, psychotic disorders, and others.

In addition, the neurodegenerative diseases are further classified into Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's Disease, amyotrophic lateral sclerosis, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Biogen Inc, Johnson and Johnson, Eli Lilly and Company Inc, Merck and Co. Inc, F. Hoffmann-La Roche AG, Novartis AG, Takeda Pharmaceuticals, Viatris, UCB, and Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the central nervous system (cns) therapeutics market analysis from 2023 to 2033 to identify the prevailing central nervous system (cns) therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the central nervous system (cns) therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global central nervous system (cns) therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Disease Type

  • Neurodegenerative Diseases
    • Disease Type
    • Alzheimer's Disease
    • Parkinson's Disease
    • Multiple Sclerosis
    • Huntington's Disease
    • Amyotrophic Lateral Sclerosis
    • Others
  • Infectious Diseases
  • CNS Cancer
  • Others
  • Neurovascular Diseases
  • CNS Trauma
  • Mental Health
    • Disease Type
    • Anxiety Disorders
    • Epilepsy
    • Mood Disorders
    • Psychotic Disorders
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Johnson and Johnson
    • Eli Lilly and Company.
    • Merck & Co Inc
    • Novartis AG
    • Biogen
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG
    • Takeda Pharmaceutical Company Ltd.
    • Viatris Inc.
    • UCB Pharma

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. High intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of the neurological conditions
      • 3.4.1.2. Rise in awareness and diagnosis of CNS disorders
      • 3.4.1.3. Surge in research and development by key players
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of central nervous system (CNS) therapeutics
    • 3.4.3. Opportunities
      • 3.4.3.1. Technological advancements in drug delivery

CHAPTER 4: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Neurovascular Diseases
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. CNS Trauma
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Mental Health
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
    • 4.4.4. Mental Health Central Nervous System (CNS) Therapeutics Market by Disease Type
  • 4.5. Neurodegenerative Diseases
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
    • 4.5.4. Neurodegenerative Diseases Central Nervous System (CNS) Therapeutics Market by Disease Type
  • 4.6. Infectious Diseases
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. CNS Cancer
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country
  • 4.8. Others
    • 4.8.1. Key market trends, growth factors and opportunities
    • 4.8.2. Market size and forecast, by region
    • 4.8.3. Market share analysis by country

CHAPTER 5: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Disease Type
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Disease Type
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Disease Type
      • 5.2.3.3. Mexico
      • 5.2.3.3.1. Market size and forecast, by Disease Type
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Disease Type
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Disease Type
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Disease Type
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Disease Type
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Disease Type
      • 5.3.3.5. Spain
      • 5.3.3.5.1. Market size and forecast, by Disease Type
      • 5.3.3.6. Rest of Europe
      • 5.3.3.6.1. Market size and forecast, by Disease Type
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Disease Type
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Disease Type
      • 5.4.3.2. China
      • 5.4.3.2.1. Market size and forecast, by Disease Type
      • 5.4.3.3. India
      • 5.4.3.3.1. Market size and forecast, by Disease Type
      • 5.4.3.4. Australia
      • 5.4.3.4.1. Market size and forecast, by Disease Type
      • 5.4.3.5. South Korea
      • 5.4.3.5.1. Market size and forecast, by Disease Type
      • 5.4.3.6. Rest of Asia-Pacific
      • 5.4.3.6.1. Market size and forecast, by Disease Type
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Disease Type
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Brazil
      • 5.5.3.1.1. Market size and forecast, by Disease Type
      • 5.5.3.2. Saudi Arabia
      • 5.5.3.2.1. Market size and forecast, by Disease Type
      • 5.5.3.3. South Africa
      • 5.5.3.3.1. Market size and forecast, by Disease Type
      • 5.5.3.4. Rest of LAMEA
      • 5.5.3.4.1. Market size and forecast, by Disease Type

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2023

CHAPTER 7: COMPANY PROFILES

  • 7.1. Johnson and Johnson
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
  • 7.2. Eli Lilly and Company.
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
    • 7.2.7. Key strategic moves and developments
  • 7.3. Merck & Co Inc
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Business performance
  • 7.4. Novartis AG
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
    • 7.4.6. Business performance
    • 7.4.7. Key strategic moves and developments
  • 7.5. Teva Pharmaceutical Industries Ltd.
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
    • 7.5.6. Business performance
    • 7.5.7. Key strategic moves and developments
  • 7.6. F. Hoffmann-La Roche AG
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Business performance
  • 7.7. Takeda Pharmaceutical Company Ltd.
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
    • 7.7.6. Business performance
  • 7.8. Viatris Inc.
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Business performance
  • 7.9. UCB Pharma
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
    • 7.9.6. Business performance
  • 7.10. Biogen
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio
    • 7.10.6. Business performance
    • 7.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 02. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEUROVASCULAR DISEASES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS TRAUMA, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR MENTAL HEALTH, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. GLOBAL MENTAL HEALTH CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 06. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 07. GLOBAL NEURODEGENERATIVE DISEASES CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 08. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 09. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS CANCER, BY REGION, 2023-2033 ($MILLION)
  • TABLE 10. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 11. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 14. U.S. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 15. CANADA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 16. MEXICO CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 17. EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 18. EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 19. GERMANY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 20. FRANCE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 21. UK CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 22. ITALY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 23. SPAIN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 24. REST OF EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 25. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 26. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 27. JAPAN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 28. CHINA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 29. INDIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 30. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 31. SOUTH KOREA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 32. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 33. LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 34. LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 36. SAUDI ARABIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 37. SOUTH AFRICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 38. REST OF LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 39. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 40. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 41. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
  • TABLE 42. JOHNSON AND JOHNSON: SERVICE SEGMENTS
  • TABLE 43. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 44. ELI LILLY AND COMPANY.: KEY EXECUTIVES
  • TABLE 45. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 46. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
  • TABLE 47. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 48. ELI LILLY AND COMPANY.: KEY STRATERGIES
  • TABLE 49. MERCK & CO INC: KEY EXECUTIVES
  • TABLE 50. MERCK & CO INC: COMPANY SNAPSHOT
  • TABLE 51. MERCK & CO INC: PRODUCT SEGMENTS
  • TABLE 52. MERCK & CO INC: PRODUCT PORTFOLIO
  • TABLE 53. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 54. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 55. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 56. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 57. NOVARTIS AG: KEY STRATERGIES
  • TABLE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 63. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 64. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 65. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
  • TABLE 66. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 67. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES
  • TABLE 68. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT
  • TABLE 69. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS
  • TABLE 70. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO
  • TABLE 71. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 72. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 73. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 74. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 75. UCB PHARMA: KEY EXECUTIVES
  • TABLE 76. UCB PHARMA: COMPANY SNAPSHOT
  • TABLE 77. UCB PHARMA: PRODUCT SEGMENTS
  • TABLE 78. UCB PHARMA: PRODUCT PORTFOLIO
  • TABLE 79. BIOGEN: KEY EXECUTIVES
  • TABLE 80. BIOGEN: COMPANY SNAPSHOT
  • TABLE 81. BIOGEN: PRODUCT SEGMENTS
  • TABLE 82. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 83. BIOGEN: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET (2023 TO 2033)
  • FIGURE 04. TOP INVESTMENT POCKETS IN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET (2024-2033)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEUROVASCULAR DISEASES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS TRAUMA, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR MENTAL HEALTH, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS CANCER, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 19. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 20. U.S. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 21. CANADA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 22. MEXICO CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 23. GERMANY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 24. FRANCE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 25. UK CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 26. ITALY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 27. SPAIN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 28. REST OF EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 29. JAPAN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 30. CHINA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 31. INDIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 32. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 33. SOUTH KOREA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 35. BRAZIL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 36. SAUDI ARABIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 37. SOUTH AFRICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 38. REST OF LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR (2020-2024)
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2024)
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY (2020-2024)
  • FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43. COMPETITIVE DASHBOARD
  • FIGURE 44. COMPETITIVE HEATMAP: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET
  • FIGURE 45. TOP PLAYER POSITIONING, 2023
  • FIGURE 46. JOHNSON AND JOHNSON: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 47. JOHNSON AND JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. JOHNSON AND JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. MERCK & CO INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. MERCK & CO INC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. MERCK & CO INC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. TAKEDA PHARMACEUTICAL COMPANY LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. UCB PHARMA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. UCB PHARMA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)